M3A backs seed-stage companies at the intersection of healthcare AI, medical technology, clinical workflows, and commercialization.
The product must reduce friction inside a real clinical or administrative workflow.
Economic value must be legible to the provider, payer, patient, or enterprise buyer.
The buyer, budget, procurement path, and sales motion must be identifiable.
FDA, CMS, privacy, and state pathways are evaluated before capital is committed.
The company should map to a durable category and credible strategic outcomes.
M3A concentrates on seed-stage opportunities where operator involvement can shape regulatory strategy, clinical validation, KOL recruitment, commercial hiring, pricing, and enterprise introductions.